A retrospective real-world experience of immunotherapy in patients with extensive stage small-cell lung cancer.

Guihuan Qiu,Fei Wang,Xiaohong Xie,Ting Liu,Chen Zeng,Ziyao Chen,Maolin Zhou,Haiyi Deng,Yilin Yang,Xinqing Lin,Zhanhong Xie,Gengyun Sun,Chengzhi Zhou,Ming Liu

Cancer medicine（2023）

引用 0|浏览2

暂无评分

摘要

ICIs combined with chemotherapy as the FL treatment could be beneficial to the ORR, DCR, PFS, and OS of ES-SCLC patients. Furthermore, ES-SCLC patients can benefit from ICIs in the second-line treatment, even if they had not received ICIs in the FL treatment.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要